Likewise, the histone demethylase, lysine-specific demethylase 1 (LSD1), has emerged as a promising therapeutic target in multiple cancers, notably in AML with a reportedly improved survival of mice engrafted with human AML cells in response to a combination of an LSD1 antagonist and a pan-histone deacetylase inhibitor [6]. This evidence concerns the gene KDM1A and acute myeloid leukemia.